
Arthur J. Gallagher & Co. (AJG) received its highest rating from Validea's Patient Investor model, based on Warren Buffett's strategy, with a score of 56%. Despite this being its top rating across 22 strategies, the 56% score falls below the 80% threshold typically indicating "some interest" for the strategy, due to a mixed fundamental profile that includes passes for earnings predictability and free cash flow but fails for return on equity and expected return.
Arthur J. Gallagher & Co. (AJG) presents a mixed fundamental profile under Validea's Buffett-inspired "Patient Investor" model, achieving a score of 56%. This rating is notably below the 80% threshold that would indicate investment interest from the strategy, suggesting it does not meet the criteria for a high-conviction position. On the positive side, AJG demonstrates operational stability, passing tests for earnings predictability, return on assets, free cash flow, and the effective use of retained earnings. However, these strengths are counteracted by significant weaknesses in key areas. The company fails the test for return on equity (ROE), a critical metric for long-term compounders. Furthermore, the model flags a "FAIL" on both the initial rate of return and the expected return, which strongly implies that the stock's current valuation is too high to offer a reasonable margin of safety or an attractive forward return according to the strategy's quantitative criteria.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment